Matching drug and trial options to patients
med fusion and GenomOncology recently announced a partnership to optimize treatment strategies based on the patient’s disease state and tumor profile
Register for free to listen to this article
Listen with Speechify
0:00
5:00
LEWISVILLE, Texas & CLEVELAND—Together, med fusion, an integrated molecular center of excellence and clinical trials service organization, and GenomOncology, an Ohio-based genomics technology and services provider, recently announced a partnership to optimize treatment strategies based on the patient’s disease state and tumor profile.
The companies believe that GenomOnoclogy’s proprietary technology platform, the GO Clinical Workbench, and support services will complement med fusion’s expanded solid tumor disease-specific panels and deliver a comprehensive laboratory report detailing relevant drug and clinical trial options.
An expansion of med fusion’s solid tumor menu is underway, including options for non-small cell lung cancer and colorectal cancer. The expanded oncology menu is powered in part by next-generation sequencing (NGS) technology that med fusion validated this summer in its CLIA- and CAP-accredited laboratory.
GenomOncology’s GO Clinical Workbench reportedly streamlines the use of NGS data in conjunction with other analytic modalities, simplifies the creation of a summary report and provides a fully traceable workflow and rules-based decision support for the clinical interpretation of genomic data.
“Cancer is a complex disease of the genome where each tumor has its own set of genetic alterations,” said Dr. Tom Lohmann, chief medical officer of med fusion. “Increased understanding of the underlying genetic changes that may be driving tumor growth or metastasis can enable precise treatment strategies tailored to the genetic profile of each patient’s cancer.”
“Genomics-based precision medicine requires the clinical interpretation of genomic data—streamlined use of next-generation sequencing information in conjunction with other analytic modalities—as well as rules-based decision support,” added Manuel Glynias, president and CEO of GenomOncology. “The availability of an expert knowledge base like My Cancer Genome, exclusively integrated with the GO Clinical Workbench, provides a clinical report that educates physicians and gives them confidence as they make treatment decisions for patients.”
